TRIFERIC AVNU

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TRIFERIC AVNU (TRIFERIC AVNU).

How it works

Triferic AVNU (ferric pyrophosphate citrate) is an iron replacement product that provides iron to hemoglobin synthesis without increasing circulating iron levels. It is taken up by transferrin and delivered to erythroid precursor cells for heme synthesis.

What the body does with it

Metabolism	Ferric pyrophosphate citrate is metabolized to release iron, which is incorporated into hemoglobin. The metabolic fate of the pyrophosphate and citrate components is not fully characterized.
Excretion	Renal excretion of iron is minimal (<5% of administered dose); most iron is incorporated into hemoglobin or stored as ferritin/hemosiderin. Biliary/fecal excretion is negligible.
Half-life	Terminal half-life of ferric pyrophosphate citrate is approximately 6-8 hours in patients with iron deficiency. In patients with normal iron stores, half-life may be longer due to redistribution. The iron component is not eliminated but conserved.
Protein binding	Transferrin: iron binds to transferrin (approximately 99.9% bound) for transport. Ferritin and hemosiderin intracellular storage.
Volume of Distribution	Vd: approximately 0.3 L/kg for the iron complex; iron distributes primarily to bone marrow, liver, and spleen. Central volume is constrained by transferrin binding.
Bioavailability	Intravenous: 100% bioavailability. Not administered orally.
Onset of Action	Intravenous: Reticulocyte response within 3-7 days; hemoglobin increase detectable within 1-2 weeks.
Duration of Action	Duration of effect on hemoglobin lasts weeks to months depending on severity of deficiency and ongoing losses. Iron stores are replenished over weeks.

Classification & Brands

Dosing & administration

Triferic Avnu (ferric pyrophosphate citrate) is administered intravenously at a dose of 2 mg iron per liter of dialysate fluid, delivered during each hemodialysis session via the dialysate line.

Dosage form	SOLUTION
Renal impairment	Triferic Avnu is specifically indicated for use in hemodialysis patients. No dose adjustment is required based on GFR as it is administered during dialysis and the drug is not dependent on renal clearance.
Liver impairment	No specific hepatic dose adjustments are provided in the label. Use with caution in patients with severe hepatic impairment due to lack of data.
Pediatric use	The safety and efficacy of Triferic Avnu in pediatric patients have not been established. No dosing recommendations are available.
Geriatric use	No specific dose adjustments are recommended for geriatric patients. Clinical studies included patients aged 65 and older, and no overall differences in safety or efficacy were observed.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for TRIFERIC AVNU (TRIFERIC AVNU).

Breastfeeding	Iron is normally present in human milk. Ferric carboxymaltose administration transfers iron into breast milk but is unlikely to cause adverse effects in the infant. M/P ratio unknown.
Teratogenic Risk	No adequate and well-controlled studies in pregnant women. Iron deficiency anemia treatment is beneficial, but ferric carboxymaltose is FDA pregnancy category B. Animal studies show no teratogenicity. Risk of fetal hypoxia from maternal anemia outweighs potential risks.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

No black box warning

Side Effect Profile

Serious Effects

Absolute Contraindications

["Known hypersensitivity to ferric pyrophosphate citrate or any component","Evidence of iron overload (e.g., serum ferritin >1000 ng/mL or transferrin saturation >50%)"]

Clinical Precautions

Precautions

["Hypersensitivity reactions including anaphylaxis have been reported.","Iron overload can occur; monitor iron status (serum ferritin, transferrin saturation) regularly.","Contains aluminum; avoid in patients with aluminum overload or toxicity risk."]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

TRIFERIC AVNU

Clinical safety rating: caution

Comprehensive clinical and safety monograph for TRIFERIC AVNU (TRIFERIC AVNU).

How it works

What the body does with it

Metabolism	Ferric pyrophosphate citrate is metabolized to release iron, which is incorporated into hemoglobin. The metabolic fate of the pyrophosphate and citrate components is not fully characterized.
Excretion	Renal excretion of iron is minimal (<5% of administered dose); most iron is incorporated into hemoglobin or stored as ferritin/hemosiderin. Biliary/fecal excretion is negligible.
Half-life	Terminal half-life of ferric pyrophosphate citrate is approximately 6-8 hours in patients with iron deficiency. In patients with normal iron stores, half-life may be longer due to redistribution. The iron component is not eliminated but conserved.
Protein binding	Transferrin: iron binds to transferrin (approximately 99.9% bound) for transport. Ferritin and hemosiderin intracellular storage.
Volume of Distribution	Vd: approximately 0.3 L/kg for the iron complex; iron distributes primarily to bone marrow, liver, and spleen. Central volume is constrained by transferrin binding.
Bioavailability	Intravenous: 100% bioavailability. Not administered orally.
Onset of Action	Intravenous: Reticulocyte response within 3-7 days; hemoglobin increase detectable within 1-2 weeks.
Duration of Action	Duration of effect on hemoglobin lasts weeks to months depending on severity of deficiency and ongoing losses. Iron stores are replenished over weeks.

Classification & Brands

Dosing & administration

Triferic Avnu (ferric pyrophosphate citrate) is administered intravenously at a dose of 2 mg iron per liter of dialysate fluid, delivered during each hemodialysis session via the dialysate line.

Dosage form	SOLUTION
Renal impairment	Triferic Avnu is specifically indicated for use in hemodialysis patients. No dose adjustment is required based on GFR as it is administered during dialysis and the drug is not dependent on renal clearance.
Liver impairment	No specific hepatic dose adjustments are provided in the label. Use with caution in patients with severe hepatic impairment due to lack of data.
Pediatric use	The safety and efficacy of Triferic Avnu in pediatric patients have not been established. No dosing recommendations are available.
Geriatric use	No specific dose adjustments are recommended for geriatric patients. Clinical studies included patients aged 65 and older, and no overall differences in safety or efficacy were observed.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for TRIFERIC AVNU (TRIFERIC AVNU).

Breastfeeding	Iron is normally present in human milk. Ferric carboxymaltose administration transfers iron into breast milk but is unlikely to cause adverse effects in the infant. M/P ratio unknown.
Teratogenic Risk	No adequate and well-controlled studies in pregnant women. Iron deficiency anemia treatment is beneficial, but ferric carboxymaltose is FDA pregnancy category B. Animal studies show no teratogenicity. Risk of fetal hypoxia from maternal anemia outweighs potential risks.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

No black box warning

Side Effect Profile

Serious Effects

Absolute Contraindications

["Known hypersensitivity to ferric pyrophosphate citrate or any component","Evidence of iron overload (e.g., serum ferritin >1000 ng/mL or transferrin saturation >50%)"]